This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Domain Therapeutics. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovator Thomas Catelain: Pioneering Heterocyclic Compounds for Neurological Treatments
Introduction: Thomas Catelain, based in Strasbourg, France, is a notable inventor recognized for his groundbreaking work in the field of pharmaceutical science. With a keen focus on the modulation of glutamatergic signaling, Catelain has been instrumental in developing innovative compounds that hold promise for treating various neurological and psychiatric disorders.
Latest Patents: Catelain is credited with a remarkable patent titled "Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors." This patent includes novel heterocyclic compounds characterized by the general formula (I) and compounds of formula (Ia). These compounds are formulated into pharmaceutical compositions aimed at treating conditions associated with altered glutamatergic signaling. Notably, they serve as modulators of the nervous system receptors sensitive to glutamate, specifically targeting metabotropic glutamate receptors (mGluRs). This invention offers potential therapeutic solutions for both acute and chronic neurological and psychiatric disorders.
Career Highlights: Thomas Catelain currently works with Domain Therapeutics, a company renowned for its innovative approach to drug discovery and development. His expertise in pharmacology and biochemistry has propelled him to the forefront of research in modulating glutamate levels, enhancing the treatment landscape for neurological conditions.
Collaborations: Throughout his career, Thomas has collaborated with esteemed colleagues such as Anne-Laure Blayo and Ismet Dorange. These partnerships have fostered an environment of creativity and innovation, driving progress in the development of novel therapeutic options.
Conclusion: Thomas Catelain's contributions to the field of pharmaceuticals not only showcase his inventive spirit but also highlight the potential impact of his research on healthcare. With a robust patent in hand, Catelain continues to push the boundaries of science, offering hope for effective treatments of neurological and psychiatric disorders. His work exemplifies the critical role of inventors in advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile